[Experiences in the treatment of advanced prostatic cancer using Turisteron with special reference to cardiovascular complications].
In a group of 44 patients with a histologically ascertained metastasizing carcinoma of the prostate gland the palliative hormone treatment with Turisteron which has been performed as routine therapy since 1982 is described. The experiences concerning the advantages of this therapy with regard to the absence of hepatotoxic side effects and the high compliance of patients, the appearance of cardiovascular complications among 39 evaluable cases are compared. A distinct reduction of these side effects is possible by an aimed cardiac therapy, prophylaxis of thrombosis and use of diuretics.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012306:Risk
C025723:ethinyl estradiol sulfonate; D004997:Ethinyl Estradiol
Erfahrungen bei der Behandlung des fortgeschrittenen Prostatakarzinoms mit Turisteron unter besonderer Berücksichtigung kardiovaskulärer Komplikationen.